Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: A prospective, randomised, multicentre study

Clinical Microbiology and Infection

Volumn 13, Issue 2, 2007, Pages 162-171

  Tamm, M ^a   Todisco, T ^b   Feldman, C ^c   Garbino, J ^d   Blasi, F ^e   Hogan, P ^f   de Caprariis, P J ^f   Hoepelman, I M ^g  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Ospedale Silvestrini   (Italy)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF MILAN   (Italy)

^f PFIZER INC   (United States)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Azithromycin; Ceftriaxone; Clarithromycin; Community acquired pneumonia; Erythromycin; Therapy

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CLARITHROMYCIN; ERYTHROMYCIN;

ADULT; AGED; ANOREXIA; APACHE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; ERYTHEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INJECTION SITE INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; MALE; MULTICENTER STUDY; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TASTE DISORDER; TREATMENT OUTCOME; URTICARIA; VOMITING;

EID: 33846307019     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01633.x     Document Type: Article

References (35)

1. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalised elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-2572.
2. Woodhead M. Community-acquired pneumonia guidelines - an international comparison. Chest 1998; 113: 1835-1875.
3. Plouffe J, Schwartz DB, Kolokathis A et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalised patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000; 44: 1796-1802.
4. Felmingham D. Respiratory pathogens: Assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms. J Antimicrob Chemother 2000; 45: 1-8.
5. Gleason PP. The emerging role of atypical pathogens in community-acquired pneumonia. Pharmacother 2002; 22 (suppl 1): 2S-11S.
6. Huchon G, Woodhead M, Gialdroni-Grassi G et al. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-991.
7. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730-1754.
8. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433.
9. San Pedro GS, Cammarata SK, Oliphant TH, Todisco T. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalised for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002; 34: 720-728.
10. Anonymous. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Joint ATS/IDSA statement. Am J Respir Crit Care Med 2005; 171: 388-416.
11. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centres in 1992 and 1993. Antimicrob Agents Chemother 1994; 38: 2419-2425.
12. Moola S, Hagberg L, Churchyard GA, Dylewski JS, Sedani S, Staley H. A multicentre study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 1999; 116: 974-983.
13. Vergis EN, Indorf A, File TM et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalised patients: A prospective, randomised, multicentre trial. Arch Intern Med 2000; 160: 1294-1300.
14. Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000; 31 (suppl 2): S35-S39.
15. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalised patients with presumed community-acquired pneumonia: A survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34: 446-452.
16. Mufson MA, Stanek RJ. Bacteraemic pneumococcal pneumonia in one American City: A 20-year longitudinal study, 1978-97. Am J Med 1999; 107: 34S-43S.
17. Guay DR. Macrolide antibiotics in paediatric infectious diseases. Drugs 1996; 51: 515-536.
18. Cook PJ, Honeybourne D. Clinical aspects of Chlamydia pneumoniae infection. Presse Med 1995; 24: 278-282.
19. Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin: Review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996; 37 (suppl C): 1-8.
20. Credito KL, Lin G, Pankuch GA, Bajaksouzian S, Jacobs MR, Appelbaum PC. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob Agents Chemother 2001; 45: 67-72.
21. Ballow CH, Amsden GW. Azithromycin: The first azalide antibiotic. Ann Pharmacother 1992; 26: 1253-1261.
22. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: A 20-year longitudinal study, 1978-97. Am J Med 1999; 107 (suppl 1A): 34S-43S.
23. Stahl JE, Barza MD, Desfardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empirical therapy on length of stay in patients hospitalised with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-2580.
24. Tong CYW, Sillis M. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993; 46: 313-317.
25. Blasi F, Boman J, Esposito G et al. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis 1999; 180: 2074-2076.
26. Abele-Horn M, Busch U, Nitzschko H et al. Molecular approaches to diagnosis of pulmonary diseases due to Mycoplasma pneumoniae. J Clin Microbiol 1998; 36: 548-551.
27. Ramirez JA, Ahkee S, Tolentino A, Miller RD, Summersgill JT. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn Microbiol Infect Dis 1996; 24: 7-14.
28. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/ IV community-acquired pneumonia patients. Respir Med 2006; 100: In press.
29. File TM, Garau J, Blasi F et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125: 1888-1901.
30. Christ-Crain M, Stolz D, Bingisser R et al. Procalciton guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006; 1740: 84-93.
31. Garbino J, Sommer R, Gerber A et al. Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland. Int J Infect Dis 2002; 6: 288-293.
32. Feldman RB, Rhew DC, Wong JY, Charles RA, Goetz MB. Azithromycin monotherapy for patients hospitalised with community-acquired pneumonia. Arch Intern Med 2003; 163: 1718-1726.
33. Frank E, Liu J, Kinasewitz G et al. A multicentre, open-label, randomised comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalised adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24: 1292-1308.
34. Blosser-Middleton R, Sahm DF, Thornsberry C et al. Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-01. Clin Microbiol Infect 2002; 8: 1-6.
35. Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost effectiveness of IV-to-oral switch therapy: Azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002; 122: 1271-1279.